Aeglea BioTherapeutics, Inc. (AGLE) Social Stream
AEGLEA BIOTHERAPEUTICS INC (AGLE) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering AEGLEA BIOTHERAPEUTICS INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-12-06 | 4 | $15 | $11 | $13.25 | $0.126 | 10415.87% |
| 2022-02-04 | 4 | $15 | $9 | $12.5 | $0.126 | 9820.63% |
| 2022-04-13 | 4 | $20 | $9 | $12 | $0.126 | 9423.81% |
| 2022-05-05 | 4 | $17 | $9 | $11.25 | $0.126 | 8828.57% |
| 2022-05-08 | 4 | $17 | $7 | $10.75 | $0.126 | 8431.75% |
| 2022-05-09 | 4 | $17 | $7 | $10.5 | $0.126 | 8233.33% |
| 2022-05-11 | 4 | $17 | $7 | $10.25 | $0.126 | 8034.92% |
| 2022-05-23 | 4 | $17 | $4 | $9.5 | $0.126 | 7439.68% |
| 2022-06-02 | 5 | $17 | $1 | $7.25 | $0.126 | 5653.97% |
| 2022-06-03 | 5 | $8 | $1 | $3.25 | $0.126 | 2479.37% |
| 2022-08-05 | 5 | $3 | $1 | $1.666 | $0.126 | 1222.22% |
| 2022-10-28 | 5 | $3 | $1 | $1.625 | $0.126 | 1189.68% |
| 2023-03-03 | 5 | $2 | $1 | $1.5 | $0.126 | 1090.48% |
The Trend in the Analyst Price Target
AGLE's average price target has moved down $13.76 over the prior 24 months.
AGLE reports an average of 191.92% for its upside potential over the past 30 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-08-09 | 5 | 3 | 1 | 1.625 | 0.412 | 294.42% |
| 2022-10-04 | 5 | 3 | 1 | 1.625 | 0.528 | 207.77% |
| 2022-11-30 | 5 | 3 | 1 | 1.875 | 0.415 | 351.81% |
| 2023-01-06 | 5 | 3 | 1 | 1.875 | 0.500 | 275% |
| 2023-03-03 | 5 | 3 | 1 | 1.875 | 0.394 | 375.89% |
AGLE Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.2 | 2 | 0 | 3 | 0 | 0 | 5 |
The Trend in the Broker Recommendations
Over the past 16 months, AGLE's average broker recommendation rating worsened by 1.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for AGLE as an investment opportunity.
- AEGLEA BIOTHERAPEUTICS INC's upside potential (average analyst target price relative to current price) is higher than 1779.72% of all US stocks.
- To contextualize these metrics, consider that out of all US stocks, AEGLEA BIOTHERAPEUTICS INC's average analyst price target is greater than 115.2% of them.
- AEGLEA BIOTHERAPEUTICS INC's variance in analysts' estimates is lower than -1199.52% of stocks in the small market cap category.
- AGLE has a greater number of analysts covering the stock than 401.05% of Healthcare stocks.
Stocks similar to AEGLEA BIOTHERAPEUTICS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are NMTR, SYBX, and ACRS.
View All Top Stocks by Price Target
Make investment decisions regarding AGLE using the data that counts. Try POWR Ratings for free.